About Amy O'Connor

Amy O'Connor leads the Digital Government Affairs team at Lilly. She is a graduate of the University of Notre Dame - Go Irish! - and the Georgetown Public Policy Institute - Hoya Saxa! Through the course of her career, Amy has spent some time in London working for the British Parliament, a few years assessing international operations for Lilly and the last six in Government Affairs focusing on strategy and business alignment. Most recently, Amy launched Lilly's digital public policy effort with LillyPad (@LillyPad) and the Campaign for Modern Medicines (@ModernMeds). Her goal is develop Lilly's engagement on public policy issues to better promote innovative public policy solutions. In her spare time, Amy can be found exploring Washington, D.C. out with her dog, playing competitive sports or cheering on her favorite team and traveling to a new country. She is also a bit of a "foodie" and enjoys trying new restaurants and bringing friends together at her favorite places. With her finger on the pulse of policy, political and advocacy worlds, Amy will share her experiences and blog about these issues on LillyPad.

An Untapped Asset for International Development

Intellectual property (IP) protections play a critical role in the creation of game changing innovation. Strong IP rights can boost economic growth in the global economy by bolstering innovation and investment in developed and developing countries alike. At this week’s Protecting Intellectual Property: The Missing Link in International Development event put on by ...

Continue reading

“Behind the Scenes” with Medical Innovation

For many people, a typical day of running errands may include a trip to the grocery store, a stop at the dry cleaner, and picking up prescribed medicines at the local pharmacy. While visiting with the pharmacist may seem like just another part of our routines, we shouldn’t take for granted the years of hard work by countless individuals that go into live-saving ...

Continue reading

A Path Forward for Orphan Drugs

This week, advocates and industry stakeholders will come together to find a path forward for the development of orphan drugs at the World Orphan Drug Congress. Coming on the heels of the annual PhRMA meeting, the conversation could not come at a better time. These treatments, frequently referred to as orphan drugs, represent the best therapies ...

Continue reading

Good News for Our Health System

I talk repeatedly about issues affecting access to medicines. So why stop now, especially during National Minority Health Month? This week’s LinkPad highlights how policies like Medicare Part D and the Affordable Care Act (ACA) have contributed to the health system and will continue to do so in the future:

Continue reading

Address the Disparity this #NMHM

A version of this post appeared on PACE, you can click here to read it.

April marks National Minority Health Month, an opportunity to raise awareness of the health disparities that continue to affect racial and ethnic minorities in the United States. This year's theme, "Prevention is Power," highlights how improved access to preventative care and medicines ...

Continue reading

A Look at Minority Health in the U.S.

A version of this post recently appeared on our Campaign for Modern Medicines blog.

Lack of health insurance negatively affects the quality and availability of health care received by minorities more than any other demographic factor. The impact of this disparity worsens when you consider that minority populations account ...

Continue reading

Partnerships for Sustained R&D

The Global Health Technologies Coalition (GHTC) recently published their 2014 report on the state of health research and development around the world. In particular, the report looked at the impact of 2013’s sequestration budget cuts on health care R&D. GHTC concludes that government spending cuts, including a 22% 

Continue reading

Collaboration Moves Us Forward

I don’t know about you, but last week’s PhRMA annual meeting has me feeling energized for the future. The meeting was a particularly great reminder of the important role collaboration plays in our industry’s efforts to deliver safe and effective treatments to patients around the world. The word collaboration came up in different ways throughout the day, but what does it mean for our industry?

Collaboration means ...

Continue reading

Exploring Diversity in Clinical Trials

All populations should have access to quality health care options.  For this to happen, the health system must reflect the diversity that exists in our country. Unfortunately, this does not happen in certain health areas. Take for example clinical trials, where minority underrepresentation has become a serious issue. This week’s LinkPad explores the problem:

Continue reading

In Case You Missed It: #PhRMA14

This week, industry stakeholders convened in Washington, DC for the 2014 PhRMA Annual Meeting. It was the largest gathering for PhRMA in over two decades, which highlighted the growing emphasis on dialogue and collaboration in the biopharmaceutical sector.

#PhRMA14 kicked off with a presentation by PhRMA Chair Bob Hugin. After discussing key ...

Continue reading
More from Amy O'Connor: 12 3 ...46 47 48